Eupraxia Pharmaceuticals

About:

Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs.

Website: http://eupraxiapharma.com

Twitter/X: Eupraxia_Pharma

Top Investors: Silicon Valley Bank, Yabema Capital

Description:

Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs. Eupraxia's product candidates have the potential to address therapeutic areas with high unmet medical needs and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

Total Funding Amount:

$102M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Victoria, British Columbia, Canada

Founded Date:

2012-01-01

Contact Email:

info(AT)eupraxiapharmaceuticals.com

Founders:

David Stadnyk

Number of Employees:

11-50

Last Funding Date:

2024-10-31

IPO Status:

Public

Industries:

© 2025 bioDAO.ai